Core Insights - Danaher Corporation's management may be manipulating investor expectations, as suggested in a previous analysis of the company's annual results [1] Company Analysis - The focus is on identifying the best businesses globally to create a long-term portfolio that can outperform the market [1]

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmid™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields. A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans. CAMBRIDGE, Mass. and FARGO, N ...

Danaher Corporation’s (DHR) first-quarter 2025 adjusted earnings of $1.88 per share beat the Zacks Consensus Estimate of $1.62. However, the bottom line decreased 2.1% year over year.Danaher reported net sales of $5.74 billion, which beat the consensus estimate of $5.56 billion. However, the metric decreased 1% year over year, owing to the lackluster performance of the Diagnostics and Life Sciences segments.DHR’s core sales were flat in the quarter. Acquisitions had a positive impact of 0.5% on quarterly sa ...

Danaher Corporation Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statem ...

Danaher Corporation (NYSE:DHR) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Tycho Peterson - Jefferies Scott Davis - Melius Research Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Daniel Brennan - TD Cowen Daniel Arias - Stifel Operator My name is Chelsy, and I will be your conference facilitator th ...

Financial Performance - Net earnings for Q1 2025 were $954 million, or $1.32 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.88[8] - Revenues decreased by 1.0% year-over-year to $5.7 billion, while non-GAAP core revenue remained flat[8] - Operating cash flow was reported at $1.3 billion, and non-GAAP free cash flow was $1.1 billion[8] - The company reported a gross profit of $3.511 billion for Q1 2025, compared to $3.487 billion in Q1 2024[14] - Operating profit for Q1 2025 was $1.274 billion, down from $1.312 billion in the same period last year[14] - Net cash provided by operating activities for the three-month period ended March 28, 2025, was $1,299 million, down from $1,739 million in the prior year[24] - Free cash flow (non-GAAP) for the three-month period ended March 28, 2025, was $1,060 million, compared to $1,448 million in the same period last year[24] Revenue Growth Expectations - For Q2 2025, the company anticipates non-GAAP core revenue growth in the low-single digits year-over-year[4] - The full year 2025 revenue growth expectation is approximately 3% year-over-year[4] - The company forecasts low-single digit core sales growth for the three-month period ending June 27, 2025, and approximately 3.0% growth for the year ending December 31, 2025[23] Earnings Guidance - The company initiated full year adjusted diluted net earnings per common share guidance in the range of $7.60 to $7.75[4] - Adjusted diluted net earnings per common share are projected to be between $7.60 and $7.75 for the year ending December 31, 2025[23] Segment Performance - Total sales for the company declined by 1.0% compared to the same period in 2024, with biotechnology segment sales growing by 6.0%[22] - Core sales growth (non-GAAP) for the biotechnology segment was 7.0%, while life sciences and diagnostics segments experienced declines of 4.0% and 1.5%, respectively[22] Strategic Focus - The company highlighted continued momentum in bioprocessing and better-than-expected respiratory demand in molecular diagnostics[2] - The company emphasized its strong balance sheet and resilient portfolio as key differentiators for 2025 and beyond[2] Cash Flow and Financing - Total cash used in financing activities was $1,255 million for the three-month period ended March 28, 2025, compared to $133 million in the prior year[24] - The company defines free cash flow as operating cash flows minus capital expenditures plus proceeds from capital disposals, highlighting its ability to generate cash for growth and investments[24] Non-GAAP Measures - The company emphasizes the importance of non-GAAP measures to provide a clearer view of its operating and financial performance, excluding items like amortization of intangible assets and restructuring charges[25][26] - The company excludes the impact of currency translation and acquisitions from core sales to better identify underlying growth trends[26][27]

WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88. Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year. Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion. Rainer M. Blai ...

Danaher Corporation (DHR) is scheduled to release first-quarter 2025 results on April 22, before market open. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The Zacks Consensus Estimate for revenues is pegged at $5.56 billion, which indicates a decrease of 4.2% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.62 per share, which decreased 2.4% in the past 60 days. The estimate indicates a decrease of 15.6% from the figure reported in the year-ago ...

Wall Street analysts expect Danaher (DHR) to post quarterly earnings of $1.62 per share in its upcoming report, which indicates a year-over-year decline of 15.6%. Revenues are expected to be $5.56 billion, down 4.2% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces it ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Danaher (DHR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on April 22, 2025, might help the stock move higher if these key numbers are better than expectations ...